191 related articles for article (PubMed ID: 37152309)
1. JAK inhibitors in systemic juvenile idiopathic arthritis.
He T; Xia Y; Luo Y; Yang J
Front Pediatr; 2023; 11():1134312. PubMed ID: 37152309
[TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Gillard L; Pouchot J; Cohen-Aubart F; Koné-Paut I; Mouterde G; Michaud M; Reumaux H; Savey L; Belot A; Fautrel B; Mitrovic S
Rheumatology (Oxford); 2023 Apr; 62(4):1594-1604. PubMed ID: 35920788
[TBL] [Abstract][Full Text] [Related]
3. Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China.
Zhu X; Weng R; Huang Y; Xu Y; Yang J; He T
Front Pediatr; 2024; 12():1349907. PubMed ID: 38550627
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.
Alexeeva E; Krekhova E; Dvoryakovskaya T; Isaeva K; Chomakhidze A; Chistyakova E; Lomakina O; Denisova R; Mamutova A; Fetisova A; Gautier M; Vankova D; Kriulin I; Saygitov R
Front Pediatr; 2023; 11():1114207. PubMed ID: 36911042
[TBL] [Abstract][Full Text] [Related]
5. Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
Chellapandian D; Milojevic D
Front Pediatr; 2023; 11():1123104. PubMed ID: 36891226
[TBL] [Abstract][Full Text] [Related]
6. Rescue of Pap-Mas in Systemic JIA Using Janus Kinase Inhibitors, Case Report and Systematic Review.
Zekre F; Duncan A; Laurent A; Tusseau M; Pescarmona R; Collardeau-Frachon S; Ohlmann C; Viel S; Reix P; Benezech S; Belot A
J Clin Med; 2023 Apr; 12(7):. PubMed ID: 37048785
[TBL] [Abstract][Full Text] [Related]
7. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis.
Kostik MM; Isupova EA; Belozerov K; Likhacheva TS; Suspitsin EN; Raupov R; Masalova VV; Chikova IA; Dubko MF; Kalashnikova OV; Chasnyk VG; Cron RQ
Front Pediatr; 2022; 10():894846. PubMed ID: 35967555
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis.
Huang Z; Lee PY; Yao X; Zheng S; Li T
Pediatrics; 2019 May; 143(5):. PubMed ID: 30948682
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R
Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666
[TBL] [Abstract][Full Text] [Related]
10. Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020: A Nationwide Retrospective Study.
Lukjanoviča K; Šlēziņa I; Dāvidsone Z; Šantere R; Budarina K; Staņēviča V
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109756
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.
Qiu L; Ma L; Xie Y; Jin J; Pan Y; Li S; Fan Z; Yu H
Pediatr Rheumatol Online J; 2024 Mar; 22(1):38. PubMed ID: 38504360
[TBL] [Abstract][Full Text] [Related]
12. Systemic juvenile idiopathic arthritis-associated lung disease: A retrospective cohort study.
Belozerov KE; Solomatina NM; Isupova EA; Kuznetsova AA; Kostik MM
World J Clin Pediatr; 2024 Mar; 13(1):88912. PubMed ID: 38596441
[TBL] [Abstract][Full Text] [Related]
13. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
14. Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
Naveen R; Jain A; Muhammed H; Gupta L; Misra DP; Lawrence A; Agarwal V; Misra R; Aggarwal A
Rheumatol Int; 2021 Mar; 41(3):625-631. PubMed ID: 33388903
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study.
Solignac M; Cabrera N; Fouillet-Desjonqueres M; Duquesne A; Laurent A; Foray AP; Viel S; Zekre F; Belot A
J Autoimmun; 2024 May; 147():103248. PubMed ID: 38797048
[TBL] [Abstract][Full Text] [Related]
16. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
17. The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis.
Çakan M; Karadağ ŞG; Tanatar A; Ayaz NA
Mod Rheumatol; 2020 Sep; 30(5):900-904. PubMed ID: 31462146
[No Abstract] [Full Text] [Related]
18. Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study.
Otar Yener G; Paç Kısaarslan A; Ulu K; Atalay E; Haşlak F; Özdel S; Bozkaya Yücel B; Gezgin Yıldırım D; Çakmak F; Öztürk K; Çakan M; Balık Z; Hasbal Akkuş C; Yıldız M; Erat T; Çetin BŞ; Yılmaz M; Bağlan E; Laçinel Gürlevik S; Atasayan V; Karadağ ŞG; Adrovic A; Çağlayan Ş; Tanatar A; Demirkan FG; Coşkuner T; Akgün Ö; Kasap Cüceoğlu M; Kavrul Kayaalp G; Şahin S; Başaran Ö; Demir F; Barut K; Çiftel M; Gürses D; Baykan A; Özsürekçi Y; Karagöz T; Sönmez HE; Bilginer Y; Aktay Ayaz N; Aydoğ Ö; Yüksel S; Sözeri B; Kasapçopur Ö; Özen S
Rheumatol Int; 2022 May; 42(5):879-889. PubMed ID: 34491393
[TBL] [Abstract][Full Text] [Related]
19. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
20. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.
Behrens EM; Beukelman T; Paessler M; Cron RQ
J Rheumatol; 2007 May; 34(5):1133-8. PubMed ID: 17343315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
